

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
24 April 2025 (24.04.2025)



(10) International Publication Number  
**WO 2025/085857 A1**

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)  
C07K 16/06 (2006.01) A61P 35/00 (2006.01)  
A61K 31/00 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2024/052127

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/591,737 19 October 2023 (19.10.2023) US

(71) Applicant: ELECTRA THERAPEUTICS, INC.

[US/US]; 201 Haskins Way, 5th Floor, South San Francisco, California 94080 (US).

(72) Inventors: DAO, Kim-Hien T.; 4315 SW 58th Avenue,

Portland, Oregon 97221 (US). PARRY, Graham C.; 428 Timberhead Lane, Foster City, California 94404 (US). PATTOU, Gary; 26353 Esperanza Drive, Los Altos Hills, California 94022 (US).

(74) Agent: DURON, David I. et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SIRP ANTIBODIES FOR TREATMENT OF CANCER




FIG. 1A

(57) Abstract: Provided herein are clinically relevant parameters for the use of SIRP antibodies, for the treatment of a cancer.

[Continued on next page]

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*